Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (6): 47-52.doi: 10.6040/j.issn.1671-7554.0.2023.0099

• 临床医学 • Previous Articles    

Cerebrospinal fluid CXCL10: a valuable biomarker for anti-NMDAR encephalitis

LI Xifeng, LI Hongmei   

  1. Department of Neurology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2023-06-06

PDF (PC)

120

Abstract: Objective To explore the inflammatory biomarkers related to anti-NMDAR encephalitis so as to provide clinical reference. Methods Serum and cerebrospinal fluid(CSF)samples were collected, including 18 cases with anti-NMDAR encephalitis(anti-NMDAR encephalitis group), 12 cases with anti-leucine rich glioma inactivated 1 protein(LGI1)antibody encephalitis(anti-LGI1 antibody encephalitis group)and 12 cases in the control group. The CSF and serum levels of CXC-motif ligand 10(CXCL10)of all three groups were detected with enzyme linked immunosorbent assay(ELISA). Data obtained were analyzed with SPSS 26.0. The differences in CXCL10 level were analyzed, and the correlation between CXCL10 level and clinical indicators of anti-NMDAR encephalitis was assessed. Results The level of CXCL10 in CSF of anti-NMDAR encephalitis group was significantly higher than that of the control group ［168.29 pg/mL(126.74 pg/mL)vs 82.11 pg/mL(43.61 pg/mL), P=0.003］, and the anti-LGI1 antibody encephalitis group ［168.29 pg/mL(126.74 pg/mL)vs 75.72 pg/mL(83.39 pg/mL), P=0.008］. The CXCL10 level in patients with anti-NMDAR encephalitis was positively correlated with the IgM level(rs=0.630, P=0.007). Conclusion CXCL10 in CSF is a valuable biomarker with specificity for anti-NMDAR encephalitis.

Key words: Anti-N-methyl-D-aspartate receptor encephalitis, Anti-leucine rich glioma inactivated 1 protein antibody encephalitis, CXC-motif ligand 10, Cerebrospinal fluid

CLC Number: 

  • R574
[1] Dalmau J, Graus F. Antibody-mediated encephalitis [J]. N Engl J Med, 2018, 378(9): 840-851.
[2] Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma [J]. Ann Neurol, 2007, 61(1): 25-36.
[3] Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol, 2011, 10(1): 63-74.
[4] Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis [J]. Lancet Neurol, 2016, 15(4): 391-404.
[5] 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50(2): 91-98. Expert consensus on diagnosis and treatment of autoimmune encephalitis in China [J]. Chinese Journal of Neurology, 2017, 50(2): 91-98.
[6] Liu JW, Liu L, Kang WT, et al. Cytokines/chemokines: potential biomarkers for non-paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis [J]. Front Neurol, 2020, 11: 582296. doi: 10.3389/fneur.2020.582296.
[7] Gresa-Arribas N, Titulaer MJ, Torrens A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study [J]. Lancet Neurol, 2014, 13(2): 167-177.
[8] Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture [J]. Neurology, 2016, 87(23): 2471-2482.
[9] Jones BE, Tovar KR, Goehring A, et al. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors [J]. Sci Transl Med, 2019, 11(500): eaaw0044. doi: 10.1126/scitranslmed.aaw0044.
[10] Deng B, Liu XN, Li X, et al. Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-D-aspartate receptor encephalitis: correlation with clinical outcome [J]. J Neuroimmunol, 2017, 305: 84-91. doi:10.1016/j.jneuroim.2017.01.02.
[11] Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid [J]. J Neuroinflammation, 2016, 13(1): 55.
[12] Leypoldt F, Höftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response [J]. JAMA neurol, 2015, 72(2): 180-186.
[13] Kothur K, Wienholt L, Mohammad SS, et al. Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis [J]. PLoS One, 2016, 11(8): e0161656. doi: 10.1371/journal.pone.0161656.
[14] Dao LM, Machule ML, Bacher P, et al. Decreased inflammatory cytokine production of antigen-specific CD4(+)T cells in NMDA receptor encephalitis [J]. J Neurol, 2021, 268(6): 2123-2131.
[15] Kothur K, Wienholt L, Brilot F, et al. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review [J]. Cytokine, 2016, 77: 227-237. doi:10.1016/j.cyto.2015.10.001.
[16] Zlotnik A, Yoshie O. The chemokine superfamily revisited [J]. Immunity, 2012, 36(5): 705-716.
[17] Lebre MC, Burwell T, Vieira PL, et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation [J]. Immunol Cell Biol, 2005, 83(5): 525-535.
[18] Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells(Th1s)and Th2s [J]. J Exp Med, 1998, 187(1): 129-134.
[19] Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine(C-X-C motif)ligand(CXCL)10 in autoimmune diseases [J]. Autoimmun Rev, 2014, 13(3): 272-280.
[20] Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients [J]. J Clin Invest, 1999, 103(6): 807-815.
[21] Yamamoto J, Adachi Y, Onoue Y, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effect populations within circulating CD4+ T cells [J]. J Leukoc Biol, 2000, 68(4): 568-574.
[22] Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes [J]. J Leukoc Biol, 1997, 61(3): 246-257.
[23] Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant(I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 [J]. J Exp Med, 1998, 187(12): 2009-2021.
[24] Hsieh MF, Lai SL, Chen JP, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus [J]. J Immunol, 2006, 177(3): 1855-1863.
[25] Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10(IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking [J]. J Immunol, 2002, 168(7): 3195-3204.
[26] Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis [J]. Neurology, 2011, 77(6): 589-593.
[27] Byun JI, Lee ST, Moon J, et al. Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis [J]. J Neuroimmunol, 2016, 297: 141-147. doi:10.1016/j.jneuroim.2016.05.023.
[28] Fife BT, Kennedy KJ, Paniagua MC, et al. CXCL10(IFN-gamma-inducible protein-10)control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis [J]. J Immunol, 2001, 166(12): 7617-7624.
[29] Roberts WK, Blachère NE, Frank MO, et al. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease [J]. Ann Neurol, 2015, 78(4): 619-629.
[30] Müller M, Carter S, Hofer MJ, et al. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity:a tale of conflict and conundrum [J]. Neuropathol Appl Neurobiol, 2010, 36(5): 368-387.
[31] Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium [J]. Clin Immunol, 2001, 98(1): 39-45.
[32] Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus [J]. Cytokine, 2000, 12(10): 1561-1565.
[33] Fujii H, Shimada Y, Hasegawa M, et al. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis [J]. J Dermatol Sci, 2004, 35(1): 43-51.
[34] Antonelli A, Ferrari SM, Corrado A, et al. CXCR3, CXCL10 and type 1 diabetes [J]. Cytokine Growth Factor Rev, 2014, 25(1): 57-65.
[35] Muehlinghaus G, Cigliano L, Huehn S, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells [J]. Blood, 2005, 105(10): 3965-3971.
[36] Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma [J]. Acta Neuropathol, 2009, 118(6): 737-743.
[37] Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases [J]. Ann Neurol, 2012, 72(2): 241-255.
[38] Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders [J]. Eur J Neurol, 2015, 22(8): 1151-1161.
[39] Hashizume M, Tan SL, Takano J, et al. Tocilizumab, A humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights [J]. Int Rev Immunol, 2015, 34(3): 265-279.
[40] Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study [J]. Neurology, 2014, 82(15): 1302-1306.
[1] HOU Shaojin, WANG Yunfeng, CAO Lili, LIU Xuewu, ZHAO Xiuhe, WANG Shengjun. Comparison of cerebrospinal fluid detection in 53 patients with neuromyelitis optica spectrum disorder and 11 patients with multiple sclerosis [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 32-37.
[2] MIAO Meng, JIA Guoyong, LIU Ying, WANG Cuilan. Clinical and radiological features of 36 adult patients with epidemic encephalitis B [J]. Journal of Shandong University (Health Sciences), 2018, 56(2): 23-27.
[3] WANG Chunlai, XU Shujun, WANG Hongliang, SHANG Jingrui. Neuroendoscopic repair of traumatic cerebrospinal fluid rhinorrhea [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 69-72.
[4] CAO Wei, XIN Tao, LIU Wei, ZHANG Yong-chao. Clinical analysis of latent cerebrospinal fluid leakage after cerebllopontine angle tumor surgery [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 78-81.
[5] LIANG Ji-ye1,2, WANG Cui-lan1, DENG Xiao-mei1. Detection of soluble Fas in patients with herpes simplex encephalitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 71-73.
[6] 李芸，杨明冲，刘师莲. High-abundant protein depletion method for cerebrospinal fluid in 2-DE analysis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(12): 113-.
[7] . Establishment of liquid chromatography technology platform of  cerebrospinal fluid for patients with multiple sclerosis in pre-and post-medication [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 85-.
[8] YANG Yin-rong,LIU Shi-lian,LIU Fu-jun,QIN Yan-jiang,BAI Shu-mei. Relation between alteration of Cystatin C in cerebrospinal fluid and GuillainBarre′syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 22-26.
[9] QIN Yan-jiang,LIU Shi-lian,YANG Yin-rong,BAI Shu-mei,ZHANG Xu-hua,DENG Xiao-mei. Proteomic analysis of cerebrospinal fluid in Demyelinative disease of the central nervous system [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 9-14.
[10] ZHANG Xuhua,LIU Shilian,QIN Yanjiang,JING Yongsheng,XU Guangrun. Proteomic analysis of multiple sclerosis cerebrospinal fluid [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 438-442.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd